8-K: Waters Corp Reports Strong Q1 2026 Results, Raises Guidance

Waters Corporation announced first quarter 2026 financial results, exceeding revenue guidance and raising full-year forecasts following the acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions businesses.

Summary

• Waters Corporation reported first quarter 2026 total revenue of $1.267 billion, surpassing guidance by $56 million.
• Organic revenue grew 13% as reported and 11% in constant currency, exceeding guidance by 200 basis points.
• The acquired Biosciences and Diagnostic Solutions businesses contributed $520 million in revenue, $40 million above expectations.
• Adjusted Earnings Per Share (EPS) increased 20% year-over-year to $2.70.
• The company is raising its full-year 2026 organic constant currency revenue growth guidance to 6.5%-8.0%.
• Full-year 2026 adjusted EPS guidance is raised to $14.40-$14.60, indicating double-digit growth.
• The first quarter results include acquisition-related purchase accounting charges, resulting in a GAAP diluted loss per share of ($0.87).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with the company exceeding expectations across key metrics and raising future guidance, indicating robust operational performance and successful acquisition integration.

Positives

• Total reported revenue of $1.267 billion exceeded the high end of guidance by $56 million.
• Organic revenue growth of 13% (11% constant currency) surpassed guidance by 200 basis points.
• Acquired businesses (Biosciences and Diagnostic Solutions) generated $520 million, $40 million above guidance.
• Adjusted EPS grew 20% year-over-year to $2.70, driven by better-than-expected revenue and margin performance.
• Full-year 2026 organic constant currency revenue growth guidance raised to 6.5%-8.0%.
• Full-year 2026 adjusted EPS guidance raised to $14.40-$14.60, representing 10%-11% growth.
• Strong performance in Analytical Sciences Division with 14% reported revenue growth.
• Biosciences Division reported $232 million in revenue, and Advanced Diagnostics Division reported $288 million.

Negatives

• Reported a GAAP diluted loss per share of ($0.87) for the first quarter of 2026, primarily due to acquisition-related purchase accounting charges including amortization of acquired intangibles and inventory step-up.
• The company is unable to provide reconciliations of forward-looking GAAP to non-GAAP financial outlook due to the unpredictability of certain charges.

Risks

• Failure to realize the anticipated benefits of the acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business.
• Delay in integrating the acquired business with the Company on the expected timeframe or at all.
• Ability to implement business strategy and achieve revenue and cost synergies.
• Risks related to anticipated progress on research programs and development of new analytical instruments.
• Manufacturing development and capabilities.
• Future financial and operational performance.
• Future economic and market conditions, including growth rates of certain markets.
• Ability to respond and adapt to changing global dynamics, including potential impacts of tariffs and supply chain challenges.

Future Outlook

The company is raising its full-year 2026 guidance for organic constant currency revenue growth to 6.5%-8.0% and expects acquired businesses to generate approximately $3.035 billion in reported revenue. Full-year 2026 adjusted EPS guidance is also raised to $14.40-$14.60, reflecting double-digit growth. For the second quarter of 2026, organic constant currency revenue growth is expected between 6.0%-8.0%, with adjusted EPS projected at $2.95-$3.05.

Management Comments

• "Thanks to the hard work of our teams, we delivered an excellent first quarter as a combined company."
• "Our Biosciences and Advanced Diagnostics Divisions are off to a strong start with a significant improvement in growth rates versus pre-close trends, due to increased execution discipline, a sharper focus on upcoming new product launches, and superb collaboration with our Analytical Sciences Division which has already enabled the realization of revenue synergies."
• "In parallel, the instrument replacement cycle, success of new product launches, and our idiosyncratic growth drivers are continuing to fuel exceptional momentum in our organic revenue growth rates."
• "As we look ahead, we are raising our guidance to reflect the increased momentum we are seeing across our businesses. Our teams are focused on executing a seamless integration, delivering industry-leading growth, and building a highly differentiated portfolio, positioning Waters for continued success for many years to come."

Industry Context

StockSavvy.ai notes that Waters Corporation's strong Q1 2026 performance, particularly the integration and revenue generation from the Becton, Dickinson and Company acquisition, highlights a trend of consolidation and synergy realization within the life sciences tools and diagnostics sector. The company's ability to exceed guidance and raise forecasts suggests robust demand for its analytical and diagnostic solutions, potentially outpacing broader industry growth.

Comparison to Industry Standards

• Waters' organic revenue growth of 11% in constant currency for Q1 2026 significantly exceeds typical growth rates for mature segments within the life sciences tools industry, which often range from 4-7%.
• The 20% year-over-year growth in Adjusted EPS is a strong indicator of effective operational leverage and margin expansion, a benchmark many competitors strive for but few consistently achieve, especially post-acquisition.
• The successful integration and revenue contribution of the acquired Biosciences and Diagnostic Solutions businesses ($520 million) at $40 million above guidance demonstrates superior execution compared to industry averages for M&A integration, where initial contributions often fall short of projections.

Stakeholder Impact

• Shareholders: Positive impact expected from raised guidance, increased EPS, and strong Q1 performance, potentially leading to share price appreciation.
• Employees: Successful integration and growth may lead to increased job security and potential for bonuses or incentives tied to performance.
• Customers: Continued innovation and expanded product portfolio from the combined entity are expected to benefit customers with advanced analytical and diagnostic solutions.
• Suppliers: Increased demand from higher revenue and production volumes may benefit suppliers.

Next Steps

• Continue executing a seamless integration of the acquired businesses.
• Focus on upcoming new product launches.
• Realize revenue synergies from the combined portfolio.
• Continue to drive momentum in organic revenue growth.
• Monitor and adapt to changing global dynamics, including supply chain challenges.

Key Dates

Recommendation

The company has demonstrated exceptional execution in integrating a significant acquisition, exceeding revenue and EPS expectations, and proactively raising full-year guidance. This strong performance, coupled with a clear strategy for future growth and synergy realization, presents a compelling investment opportunity.

Keywords

Waters Corporation, 8-K, Financial Results, Q1 2026, Acquisition, Biosciences, Diagnostic Solutions, Revenue Growth